Creative Biogene Offers C. elegans Drug Screening Service to Identify Drug Targets and Mechanisms for Particular Needs

Creative Biogene announced the release of its C. elegans drug screening services to identify drug targets and mechanisms in order to satisfy diverse needs.

New York, USA – February 23, 2022 – C. elegans Platform, the division of Creative Biogene, is a professional provider of C. elegans model services. Creative Biogene is committed to providing researchers with the most reliable research services, including comprehensive data analysis, services involving C. elegans genome editing, C. elegans stress response modeling, aging research, drug screening, C. elegans biology. Recently, Creative Biogene announced the release of its C. elegans drug screening services to identify drug targets and mechanisms in order to satisfy diverse needs.

Drug screening is labor-intensive and time-consuming, and recent advances in high-throughput workflows, imaging platforms, and data analysis software have propelled worms as a viable option for automated high-throughput drug screening. Creative Biogene provides advanced instrumentation and best-in-class solutions to help customers screen drugs, including anti-infective compounds, anti-neurodegenerative drugs, life-extending compounds and anti-cancer drugs. In addition, the platform offers a customized pipeline to identify drug targets and mechanisms to meet customers’ specific needs. The available services offered by Creative Biogene include:

Anti-infective compounds screening service is able to identify molecules that promote host survival innate immune responses and compounds that interfere with bacterial virulence mechanisms but also provides in-assay screening for toxic molecules. Creative Biogene provides anti-infective drug screening services, including immune-stimulating compounds, anti-virulence compounds, and pathogen-targeting compounds.

Creative Biogene provides the most common drug screening against neurodegenerative diseases service based on high-throughput automated drug screening system involving Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS). Creative Biogene also provides an automated platform for identifying potential long-lived compounds utilizing differential C. elegans phenotypic and biochemical changes associated with mild mitochondrial stress as surrogate markers for establishing phenotype-based screens.

In addition, Creative Biogene provides related signaling pathway mutants for the identification of anticancer drugs. Additionally, an automated high-content drug screening system based on the COPASTM Worm Sorter and Spot Detector is used to accelerate and improve the drug screening process.

“We have a professional team with extensive experience in the field of C. elegans research and advanced instrumentation, enabling Creative Biogene to develop a series of systematic platforms and complete independent research.” said Marcia Brady, the marketing director of Creative Biogene, “Creative Biogene is a dedicated provider of C. elegans model services. We are committed to expediting the high-quality achievement of our clients’ research goals and providing customized services to meet the specific needs of our clients’ research.”

About C. elegans platform

As a professional provider of C. elegans model services, C. elegans platform is dedicated to accelerating the speed of customers’ research projects. The highly trained staff always strictly implement quality control procedures to deliver customer results on time without compromising quality. With a professional platform, Creative Biogene is capable to provide customers with unique products and services according to scientific research needs.

Media Contact
Company Name: Creative Biogene
Contact Person: Marcia Brady
Email: Send Email
Phone: 1-631-386-8241
Country: United States